Fortress Biotech (NASDAQ:FBIO) CFO David Jin Acquires 25,000 Shares of Company Stock

Fortress Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CFO David Jin bought 25,000 Fortress Biotech shares at an average $1.91, spending $47,750 and increasing his holdings to about 1.69 million shares. He also made two additional purchases recently, while CEO Lindsay Rosenwald bought shares as well.
  • FBIO shares fell 5.7% to $1.78 on Thursday. In its latest quarter, Fortress reported a loss of $0.23 per share, narrower than expected, but revenue of $19.16 million came in below estimates.
  • Analysts have a consensus Hold rating on the stock; two rate it Buy, one Hold, and one Sell.
  • Interested in Fortress Biotech? Here are five stocks we like better.

Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CFO David Jin bought 25,000 shares of the business's stock in a transaction dated Wednesday, November 18th. The shares were acquired at an average cost of $1.91 per share, for a total transaction of $47,750.00. Following the purchase, the chief financial officer owned 1,692,761 shares of the company's stock, valued at approximately $3,233,173.51. The trade was a 1.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

David Jin also recently made the following trade(s):

  • On Thursday, November 19th, David Jin purchased 7,605 shares of Fortress Biotech stock. The stock was acquired at an average price of $1.87 per share, for a total transaction of $14,221.35.
  • On Tuesday, November 17th, David Jin purchased 15,000 shares of Fortress Biotech stock. The shares were acquired at an average cost of $1.72 per share, with a total value of $25,800.00.

Fortress Biotech Trading Down 5.7%

Shares of FBIO stock traded down $0.11 on Thursday, reaching $1.78. 194,841 shares of the company's stock were exchanged, compared to its average volume of 586,980. The company's fifty day simple moving average is $2.08 and its 200 day simple moving average is $2.70. Fortress Biotech, Inc. has a 52 week low of $1.64 and a 52 week high of $4.53. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $60.16 million, a PE ratio of 0.78 and a beta of 1.27.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The company had revenue of $19.16 million for the quarter, compared to the consensus estimate of $21.57 million.

Recent Fortress Biotech Headlines

These are some of the FBIO headlines that stood out recently:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

Analysts Set New Price Targets

FBIO has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Fortress Biotech from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings lowered shares of Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, October 23rd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Fortress Biotech presently has a consensus rating of "Hold" and an average price target of $17.00.

Read Our Latest Analysis on FBIO

Institutional Trading of Fortress Biotech

Large investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in Fortress Biotech during the 3rd quarter worth $462,000. Squarepoint Ops LLC purchased a new position in shares of Fortress Biotech during the second quarter valued at $47,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 18,490 shares in the last quarter. Hedge funds and other institutional investors own 96.51% of the company's stock.

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fortress Biotech Right Now?

Before you consider Fortress Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.

While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines